The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
Open accessAbstract
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace oral glucocorticoids without compromising efficacy. In this randomized, placebo-controlled trial, adults with newly diagnosed or relapsing vasculitis received placebo plus prednisone starting at 60 mg daily (control group), avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily), or avacopan (30 mg, twice daily) without prednisone. All patients received cyclophosphamide or rituximab. The primary efficacy measure was the proportion of patients achieving a ≥50% reduction in Birmingham Vasculitis Activity Score by week 12 and no worsening in any body system. We enrolled 67 patients, 23 in the control and 22 in each of the avacopan groups. Clinical response at week 12 was achieved in 14 of 20 (70.0%) control patients, 19 of 22 (86.4%) patients in the avacopan plus reduced-dose prednisone group (difference from control 16.4%; two-sided 90% confidence limit, −4.3% to 37.1%; P =0.002 for noninferiority), and 17 of 21 (81.0%) patients in the avacopan without prednisone group (difference from control 11.0%; two-sided 90% confidence limit, −11.0% to 32.9%; P =0.01 for noninferiority). Adverse events occurred in 21 of 23 (91%) control patients, 19 of 22 (86%) patients in the avacopan plus reduced-dose prednisone group, and 21 of 22 (96%) patients in the avacopan without prednisone group. In conclusion, C5a receptor inhibition with avacopan was effective in replacing high-dose glucocorticoids in treating vasculitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Self-citation2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
Kallenberg, C. G. M., Lamprecht, P., Hoffman, G. C., Rasmussen, N., Pusey, C. D., Özen, S., Matteson, E. L., Merkel, P. A., Flores-Suarez, L. F., Bacon, P. A., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tnnw-jw94 · Cited by 1,255
Self-citationEULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
Self-citationCyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis
Fauci, A. S., Katz, P., Haynes, B. F., & Wolff, S. M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908023010503 · Cited by 526
C5a-induced expression of P-selectin in endothelial cells.
Foreman, K. E., Vaporciyan, A. A., Bonish, B. K., Jones, M. L., Johnson, K. J., Glovsky, M. M., Eddy, S. M., & Ward, P. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117430 · Cited by 473
C5a Receptor Mediates Neutrophil Activation and ANCA-Induced Glomerulonephritis
Schreiber, A., Xiao, H., Jennette, J. C., Schneider, W., Luft, F. C., & Kettritz, R. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050497 · Cited by 451
Little, M. A., Nightingale, P., Verburgh, C. A., Hauser, T., De Groot, K., Savage, C., Jayne, D., & Harper, L. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.109389 · Cited by 440
Self-citationTesch, G. H. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00016.2008 · Cited by 417
C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN
Xiao, H., Dairaghi, D. J., Powers, J. P., Ertl, L. S., Baumgart, T., Wang, Y., Seitz, L. C., Penfold, M. E. T., Gan, L., Hu, P., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020143 · Cited by 353
Self-citationComplement alternative pathway acts as a positive feedback amplification of neutrophil activation
Camous, L., Roumenina, L., Bigot, S., Brachemi, S., Frémeaux-Bacchi, V., Lesavre, P., & Halbwachs-Mecarelli, L. (2011) · Blood · doi:10.1182/blood-2010-05-283564 · Cited by 244
Complement C3a and C5a Induce Different Signal Transduction Cascades in Endothelial Cells
Schraufstatter, I. U., Trieu, K., Sikora, L., Sriramarao, P., & DiScipio, R. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.2102 · Cited by 233
Complement-induced granulocyte aggregation in vivo.
Hammerschmidt, D. E., Harris, P. D., Wayland, J. H., et al. (1981) · PubMed · Cited by 164
Predictors of survival and organ damage in Wegener's granulomatosis
Koldingsnes, W. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.5.572 · Cited by 157
Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients
Charlier, C., Hénégar, C., Launay, O., Pagnoux, C., BEREZNE, A., Bienvenu, B., Cohen, P., Mouthon, L., & Guillevin, L. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088302 · Cited by 156
Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics
Wolkow, P. P., Niewczas, M. A., Perkins, B., Ficociello, L. H., Lipinski, B., Warram, J. H., & Krolewski, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050556 · Cited by 155
Robson, J. C., Doll, H., Suppiah, R., Floßmann, O., Harper, L., Höglund, P., Jayne, D. R. W., Mahr, A., Westman, K. W. A., & Luqmani, R. A. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu366 · Cited by 154
Self-citationBekker, P. J., Dairaghi, D. J., Seitz, L., Leleti, M. R., Wang, Y., Ertl, L. S., Baumgart, T., Shugarts, S. B., Lohr, L., Dang, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164646 · Cited by 153
Self-citationZheng, D., Wolfe, M., Cowley, B. D., Wallace, D. P., Yamaguchi, T., & Grantham, J. J. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088720.61783.19 · Cited by 138
Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
Mcgregor, J., Hogan, S. L., Hu, Y., Jennette, C. E., Falk, R. J., & Nachman, P. H. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05610611 · Cited by 130
Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis
Tam, F. W. K. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh487 · Cited by 124
Miloslavsky, E. M., Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., Clair, E. W. S., Tchao, N. K., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38044 · Cited by 123
Nadkarni, G. N., Rao, V. S., Ismail‐Beigi, F., Fonseca, V. A., Shah, S. V., Simonson, M. S., Cantley, L. G., Devarajan, P., Parikh, C. R., & Coca, S. G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12051115 · Cited by 115
Lymphopenia and Treatment-Related Infectious Complications in ANCA-Associated Vasculitis
Goupil, R., Brachemi, S., Nadeau‐Fredette, A., Déziel, C., Troyanov, Y., Lavergne, V., & Troyanov, S. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07300712 · Cited by 107
Endothelium-Neutrophil Interactions in ANCA-Associated Diseases
Halbwachs‐Mecarelli, L., & Lesavre, P. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012020119 · Cited by 102
Evidence‐based treatment of systemic vasculitis
Jayne, D. R. W. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.585 · Cited by 96
Self-citationDeoxyspergualin in relapsing and refractory Wegener's granulomatosis
Floßmann, O., Baslund, B., Bruchfeld, A. N., Tervaert, J.-W. C., Hall, C., Heinzel, P. A., Hellmich, B., Luqmani, R. A., Nemoto, K., Tesař, V., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092429 · Cited by 84
Self-citationMortality in Wegener's granulomatosis: a bimodal pattern
Luqmani, R. A., Suppiah, R., Edwards, C. J., Phillip, R., Maskell, J., Culliford, D. J., Jayne, D. R. W., Morishita, K. A., & Arden, N. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq351 · Cited by 80
Self-citationAntineutrophil cytoplasm antibody–associated vasculitis: recent developments
Furuta, S., & Jayne, D. R. W. (2013) · Kidney International · doi:10.1038/ki.2013.24 · Cited by 71
Self-citationCorral-Gudino, L., Borao‐Cengotita‐Bengoa, M., del Pino‐Montes, J., & Lerma-Márquez, J. L. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker112 · Cited by 64
With Complements from ANCA Mice
Kettritz, R. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101043 · Cited by 21
Wegener's granulomatosis in Finland in 1981–2000: risk of dialysis-dependent renal disease
Takala, J., Kautiainen, H., Finne, P., & Leirisalo‐Repo, M. (2011) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2010.533693 · Cited by 9
Cited by
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
Self-citationRetractedRomagnani, P., Remuzzi, G., Glassock, R., Levin, A., Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & Anders, H.-J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.88 · Cited by 996
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Kitching, A. R., Anders, H.-J., Basu, N., Brouwer, E., Gordon, J., Jayne, D. R., Kullman, J., Lyons, P. A., Merkel, P. A., Savage, C. O. S., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0204-y · Cited by 928
Self-citationNeutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 653
Metadata
- Authors
- Jayne, D. R. W., Bruchfeld, A. N., Harper, L., Schaier, M., Venning, M. C., Hamilton, P., Burst, V., Grundmann, F., Jadoul, M., Szombati, I., Tesař, V., Segelmark, M., Potarca, A., Schall, T. J., Bekker, P., & for the CLEAR Study Group
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-04-11
- Volume
- 28
- Issue
- 9
- Pages
- 2756-2767
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2607382700
- Cited by
- 607
- References
- 33
- FWCI
- 47.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.